FinancialBuzz.com’s latest
The Buzz
Show: Featuring Our Corporate News Recap on “
Can-Fite BioPharma
Shares Surge Following
Exclusive Distribution Agreement with Ewopharma
”
Can-Fite BioPharma (NYSE: CANF)
surged over 103% in premarket trading after announcing an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson and Namodenoson.
Under the agreement, Ewopharma gains the right to market and sell Piclidenoson in Central Eastern European countries and Namodenoson in Central Eastern European countries as well as Switzerland.
Can-Fite BioPharma Ltd. is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company’s lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite’s liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction.
For more information, please visit:
Can-Fite BioPharma Ltd.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post
“The Buzz” Show: Can-Fite BioPharma (NYSE: CANF) Exclusive Distribution Agreement with Ewopharma
first appeared on
Financial Buzz
.
For further details see:
“The Buzz” Show: Can-Fite BioPharma (NYSE: CANF) Exclusive Distribution Agreement with Ewopharma